303 related articles for article (PubMed ID: 22551036)
1. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.
Anton RF; Voronin KK; Randall PK; Myrick H; Tiffany A
Alcohol Clin Exp Res; 2012 Nov; 36(11):2000-7. PubMed ID: 22551036
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
[TBL] [Abstract][Full Text] [Related]
3. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.
Anton RF; Voronin KE; Book SW; Latham PK; Randall PK; Glen WB; Hoffman M; Schacht JP
Alcohol Clin Exp Res; 2020 Oct; 44(10):2084-2096. PubMed ID: 32772383
[TBL] [Abstract][Full Text] [Related]
4. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.
Schacht JP; Anton RF; Voronin KE; Randall PK; Li X; Henderson S; Myrick H
Neuropsychopharmacology; 2013 Feb; 38(3):414-22. PubMed ID: 23032071
[TBL] [Abstract][Full Text] [Related]
5. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.
Kranzler HR; Armeli S; Covault J; Tennen H
Addict Biol; 2013 Jan; 18(1):193-201. PubMed ID: 22784013
[TBL] [Abstract][Full Text] [Related]
6. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR
Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981
[TBL] [Abstract][Full Text] [Related]
7. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study).
Morley KC; Kranzler HR; Luquin N; Baillie A; Shanahan M; Trent R; Teesson M; Haber PS
Trials; 2018 Aug; 19(1):443. PubMed ID: 30115121
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms of the mu-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment.
Ray LA; Miranda R; Tidey JW; McGeary JE; MacKillop J; Gwaltney CJ; Rohsenow DJ; Swift RM; Monti PM
J Abnorm Psychol; 2010 Feb; 119(1):115-25. PubMed ID: 20141248
[TBL] [Abstract][Full Text] [Related]
9. Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot investigation.
Ray LA; Hutchison KE; Ashenhurst JR; Morrow AL
Alcohol Clin Exp Res; 2010 Aug; 34(8):1479-87. PubMed ID: 20528823
[TBL] [Abstract][Full Text] [Related]
10. Genetic moderators of naltrexone's effects on alcohol cue reactivity.
McGeary JE; Monti PM; Rohsenow DJ; Tidey J; Swift R; Miranda R
Alcohol Clin Exp Res; 2006 Aug; 30(8):1288-96. PubMed ID: 16899031
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.
Ray LA; Bujarski S; Chin PF; Miotto K
Neuropsychopharmacology; 2012 Jan; 37(2):445-55. PubMed ID: 21900886
[TBL] [Abstract][Full Text] [Related]
12. Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.
Oslin DW; Leong SH; Lynch KG; Berrettini W; O'Brien CP; Gordon AJ; Rukstalis M
JAMA Psychiatry; 2015 May; 72(5):430-7. PubMed ID: 25760804
[TBL] [Abstract][Full Text] [Related]
13. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach.
Oroszi G; Anton RF; O'Malley S; Swift R; Pettinati H; Couper D; Yuan Q; Goldman D
Alcohol Clin Exp Res; 2009 Mar; 33(3):383-93. PubMed ID: 19053977
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial.
Schacht JP; Hoffman M; Chen BH; Anton RF
Pharmacogenomics J; 2022 Feb; 22(1):1-8. PubMed ID: 34381173
[TBL] [Abstract][Full Text] [Related]
15. Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol.
Ray LA; Bujarski S; Squeglia LM; Ashenhurst JR; Anton RF
Alcohol Alcohol; 2014; 49(3):261-70. PubMed ID: 24421289
[TBL] [Abstract][Full Text] [Related]
16. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
Ray LA; Hutchison KE
Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
[TBL] [Abstract][Full Text] [Related]
17. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH;
Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034
[TBL] [Abstract][Full Text] [Related]
18. Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.
Tidey JW; Monti PM; Rohsenow DJ; Gwaltney CJ; Miranda R; McGeary JE; MacKillop J; Swift RM; Abrams DB; Shiffman S; Paty JA
Alcohol Clin Exp Res; 2008 Jan; 32(1):58-66. PubMed ID: 18028530
[TBL] [Abstract][Full Text] [Related]
19. [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine].
Kibitov АО; Krupitsky ЕМ; Blokhina ЕА; Verbitskaya ЕV; Brodyansky VМ; Alekseeva NP; Bushara NМ; Yaroslavtseva ТS; Palatkin VY; Masalov DV; Burakov АМ; Romanova ТN; Sulimov GY; Grinenko AY; Kosten Т; Nielsen D; Zvartau EE
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11. Vyp. 2):36-48. PubMed ID: 28300812
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial.
Ray LA; Green R; Roche DJO; Bujarski S; Hartwell EE; Lim AC; Rohrbaugh T; Ghahremani D; Hutchison K; Miotto K
Alcohol Clin Exp Res; 2018 Mar; 42(3):613-623. PubMed ID: 29265379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
